EP
TSHA icon

Essential Partners’s Taysha Gene Therapies TSHA Stock Holding History

Essential Partners’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.23K Hold
327
– – ﹤0.01% 1930
2026
Q1 		$1.46K Hold
327
– – ﹤0.01% 2110
2025
Q4 		$1.8K Hold
327
– – ﹤0.01% 1841
2025
Q3 		$1.07K Hold
327
– – ﹤0.01% 2000
2025
Q2 		$755 Buy
+327
New +$710 ﹤0.01% 1581

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essential Partners's TSHA Position: Q2 2026 in Review

Essential Partners held its Taysha Gene Therapies (TSHA) position steady in Q2 2026 at 327 shares worth $2.23K. The position accounts for ﹤0.01% of the portfolio, ranked #1930.

Essential Partners first reported a position in TSHA in Q2 2025 and has held it in 5 quarters since. 209 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Essential Partners held 327 shares of Taysha Gene Therapies worth $2.23K as of Q2 2026.
  • Essential Partners left its Taysha Gene Therapies share count unchanged in Q2 2026.
  • Taysha Gene Therapies made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #1930 holding.
  • Essential Partners first reported a position in Taysha Gene Therapies in Q2 2025 and has held it in 5 quarters since.
  • 209 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.